Exploring chamazulene as a novel therapeutic agent for breast cancer <i>in silico</i> and <i>in vitro</i>: apoptosis induction, cell cycle regulation, and antimetastatic effects.

Front Pharmacol · 2025 · PMC12531213 · PMID 41111502

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The enrichment p-value was calculated to be less than 1.0e-16, signifying a highly significant interaction network.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Exploring chamazulene as a novel therapeutic agent for breast cancer &lt;i&gt;in silico&lt;/i&gt; and &lt;i&gt;in vitro&lt;/i&gt;: apoptosis induction, cell cycle regulation, and antimetastatic effects.

The sentences

Exploring chamazulene as a novel therapeutic agent for breast cancer <i>in silico</i> and <i>in vitro</i>: apoptosis induction, cell cycle regulation, and antimetastatic effects.